[DISCLOSURE]
Hanmi Pharmaceutical (128940) said on Sept. 30 that the contract regarding its lung cancer treatment HM61713 with German pharmaceutical firm, Boehringer Ingelheim has been terminated.
The German company will be returning its license obtained in 2015, but Hanmi Pharma is not obligated to refund the contract fee worth US$65 million.
(
theinvestor@heraldcorp.com)
